Go Pro
→ Your book attached (From Profits Run) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Celcuity, Inc. stock logo
CELC
Celcuity
$78.61
-1.1%		$88.00
$44.42
▼
$151.02
$3.86B0.191.07 million shs2,844 shs
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
$15.07
-1.9%		$19.62
$5.68
▼
$23.19
$977.24M0.02900,012 shs2,412 shs
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
$10.88
-0.8%		$11.39
$6.28
▼
$13.11
$3.69B-0.17225,897 shs3,016 shs
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
$32.30
-0.9%		$33.54
$25.77
▼
$43.15
$4.06B0.693.05 million shs18,542 shs
7 Stocks That Will Be Magnificent in 2026 Cover
7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Celcuity, Inc. stock logo
CELC
Celcuity
+2.77%-0.59%-10.71%-26.34%+60.97%
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
+0.79%-9.01%-30.45%-12.93%+158.85%
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
-3.26%-2.66%-1.08%-7.58%+14.63%
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
+2.48%-21.73%-0.55%-12.93%+24.05%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Celcuity, Inc. stock logo
CELC
Celcuity
$78.61
-1.1%		$88.00
$44.42
▼
$151.02
$3.86B0.191.07 million shs2,844 shs
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
$15.07
-1.9%		$19.62
$5.68
▼
$23.19
$977.24M0.02900,012 shs2,412 shs
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
$10.88
-0.8%		$11.39
$6.28
▼
$13.11
$3.69B-0.17225,897 shs3,016 shs
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
$32.30
-0.9%		$33.54
$25.77
▼
$43.15
$4.06B0.693.05 million shs18,542 shs
7 Stocks That Will Be Magnificent in 2026 Cover
7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Celcuity, Inc. stock logo
CELC
Celcuity
+2.77%-0.59%-10.71%-26.34%+60.97%
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
+0.79%-9.01%-30.45%-12.93%+158.85%
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
-3.26%-2.66%-1.08%-7.58%+14.63%
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
+2.48%-21.73%-0.55%-12.93%+24.05%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Celcuity, Inc. stock logo
CELC
Celcuity
2.83
Moderate Buy$154.2596.21% Upside
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
2.78
Moderate Buy$33.71123.79% Upside
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
3.00
Buy$20.5088.45% Upside
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
2.75
Moderate Buy$99.67208.58% Upside

Current Analyst Ratings Breakdown

Latest CGEM, TLX, CELC, and VKTX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/30/2026
Celcuity, Inc. stock logo
CELC
Celcuity
Needham & Company LLC logo
Needham & Company LLC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$140.00 ➝ $134.00
9/25/2026
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$30.00 ➝ $35.00
9/25/2026
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
BTIG Research logo
BTIG Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$40.00
9/25/2026
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$20.00
9/23/2026
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
Truist Financial Corporation logo
Truist Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$83.00 ➝ $87.00
9/23/2026
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
Wedbush logo
Wedbush
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform$22.00
9/22/2026
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
Oppenheimer Holdings, Inc. logo
Oppenheimer
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$120.00
9/22/2026
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
9/22/2026
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight
9/21/2026
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold ➝ Moderate Buy
9/17/2026
Celcuity, Inc. stock logo
CELC
Celcuity
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOverweight$157.00
(Data available from 10/1/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Celcuity, Inc. stock logo
CELC
Celcuity
N/AN/AN/AN/A$2.17 per shareN/A
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
N/AN/AN/AN/A$6.92 per shareN/A
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
$803.79M4.60$0.04 per share268.95$1.23 per share8.84
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
N/AN/AN/AN/A$5.65 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Celcuity, Inc. stock logo
CELC
Celcuity
-$177.04M-$4.30N/AN/AN/AN/A-350.78%-41.54%11/11/2026 (Estimated)
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
-$219.88M-$3.10N/AN/AN/AN/A-52.89%-48.18%11/5/2026 (Estimated)
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
-$7.12MN/AN/A40.29N/AN/AN/AN/AN/A
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
-$359.64M-$4.66N/AN/AN/AN/A-94.56%-82.75%10/28/2026 (Estimated)

Latest CGEM, TLX, CELC, and VKTX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
10/28/2026Q3 2026
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
-$1.07N/AN/AN/AN/AN/A
8/13/2026Q2 2026
Celcuity, Inc. stock logo
CELC
Celcuity
-$1.16-$1.44-$0.28-$1.44$4.42 millionN/A
8/6/2026Q2 2026
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
-$0.7993-$0.81-$0.0107-$0.81$3.67 millionN/A
7/29/2026Q2 2026
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
-$1.21-$1.10+$0.11-$1.10N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Celcuity, Inc. stock logo
CELC
Celcuity
N/AN/AN/AN/AN/A
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
N/AN/AN/AN/AN/A
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
N/AN/AN/AN/AN/A
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Celcuity, Inc. stock logo
CELC
Celcuity
6.04
8.93
8.93
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
N/A
8.42
8.42
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
1.16
2.01
1.85
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
N/A
4.72
4.72

Institutional Ownership

CompanyInstitutional Ownership
Celcuity, Inc. stock logo
CELC
Celcuity
63.33%
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
86.31%
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
N/A
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
76.03%

Insider Ownership

CompanyInsider Ownership
Celcuity, Inc. stock logo
CELC
Celcuity
13.33%
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
8.60%
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
N/A
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
5.30%
CompanyEmployeesShares OutstandingFree FloatOptionable
Celcuity, Inc. stock logo
CELC
Celcuity
15548.93 million42.41 millionOptionable
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
10964.36 million58.82 millionOptionable
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
1,152339.89 millionN/AN/A
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
65125.99 million119.31 millionOptionable

Recent News About These Companies

Laboratory workstation with a centrifuge, pipettes, sample racks, and automated liquid-handling equipment on a metal bench.
3 Emerging Biotech Stocks With Significant Upside Potential (VKTX)
...
 |  marketbeat.comhttps://www.marketbeat.com/articles/3-emerging-biotech-stocks-with-significant-upside-potential/
Viking Therapeutics, Inc. (VKTX) Rises As Market Takes a Dip: Key Facts
September 30 at 6:50 PM  |  zacks.comhttps://www.zacks.com/stock/news/2998508/viking-therapeutics-inc-vktx-rises-as-market-takes-a-dip-key-facts?cid=cs-stocknewsapi-ft-fundamental_analysis|yseop_template_6v1-2998508
Viking Therapeutics, Inc. (VKTX) Rises As Market Takes a Dip: Key Facts
September 30 at 6:26 PM  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/viking-therapeutics-inc-vktx-rises-205006106.html
Viking Therapeutics Stock Soars 36% on Weight-Loss Drug Data. Why It's Not Too Late to Buy the Stock.
September 30 at 6:26 PM  |  fool.comhttps://www.fool.com/investing/2026/09/30/viking-therapeutics-stock-soars-20-on-weight-loss/
Eli Lilly Stock Barely Moved Following Viking Therapeutics' Impressive Clinical Results. Here's Why.
September 29 at 6:22 PM  |  fool.comhttps://www.fool.com/investing/2026/09/29/eli-lilly-stock-barely-moved-following-viking-ther/
3 Non-AI Growth Stocks That Have Massive Upside
September 29 at 1:21 PM  |  fool.comhttps://www.fool.com/investing/2026/09/29/3-non-ai-growth-stocks-that-have-massive-upside/
VKTX Stock Logs 3-Day Losing Streak As $548M Raise Closes — Retail Calls Dip An ‘Easy Buy’ Amid Buyout Talks
September 29 at 3:20 AM  |  stocktwits.comS
Viking Therapeutics Announces Closing of Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes, Including Full Exercise of Underwriters' Options to Purchase ...
September 28 at 5:17 PM  |  markets.ft.comhttps://markets.ft.com/data/announce/detail?dockey=600-202609281630PR_NEWS_USPRX____LA58434-1
Viking Therapeutics Announces Closing of Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes, Including Full Exercise of Underwriters' Options to Purchase Additional Shares of Common Stock and Convertible Senior Notes
September 28 at 5:17 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/viking-therapeutics-announces-closing-concurrent-203000029.html
Viking Therapeutics Announces Closing of Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes, Including Full Exercise of Underwriters' Options to Purchase Additional Shares of Common Stock and Convertible Senior Notes
September 28 at 4:30 PM  |  prnewswire.comhttps://www.prnewswire.com/news-releases/viking-therapeutics-announces-closing-of-concurrent-upsized-offerings-of-common-stock-and-convertible-senior-notes-including-full-exercise-of-underwriters-options-to-purchase-additional-shares-of-common-stock-and-convertible-sen-302891919.html
Wall Street Analysts Think Viking Therapeutics (VKTX) Is a Good Investment: Is It?
September 28 at 12:16 PM  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/wall-street-analysts-think-viking-123002734.html
Viking Therapeutics Adds Weight Loss Maintenance As Potential New Growth Driver
September 28 at 11:56 AM  |  seekingalpha.comhttps://seekingalpha.com/article/4950302-viking-therapeutics-adds-weight-loss-maintenance-potential-new-growth-driver
Kuehn Law Encourages Investors of Viking Therapeutics, Inc. to Contact Law Firm
September 28 at 11:12 AM  |  prnewswire.comhttps://www.prnewswire.com/news-releases/kuehn-law-encourages-investors-of-viking-therapeutics-inc-to-contact-law-firm-302891041.html
Wall Street Analysts Think Viking Therapeutics (VKTX) Is a Good Investment: Is It?
September 28 at 10:31 AM  |  zacks.comhttps://www.zacks.com/stock/news/2996571/wall-street-analysts-think-viking-therapeutics-vktx-is-a-good-investment-is-it?cid=cs-stocknewsapi-ft-fundamental_analysis|average_broker_rating-2996571
Viking Therapeutics (VKTX) Delivers Great VK2735 Results: Here's a Word of Caution
September 27, 2026  |  fool.comhttps://www.fool.com/investing/2026/09/27/viking-therapeutics-delivers-great-vk2735-results/
3 Numbers From Viking Therapeutics' Weight-Loss Drug Trial That Have Wall Street Buzzing
September 27, 2026  |  fool.comhttps://www.fool.com/investing/2026/09/27/numbers-viking-therapeutics-weight-loss-drug/
Viking Therapeutics Stock Falls 15% After $483 Mln Equity And Convertible Notes Offering
September 26, 2026  |  rttnews.comhttps://www.rttnews.com/3693742/viking-therapeutics-stock-falls-15-after-483-mln-equity-and-convertible-notes-offering.aspx
Is Viking Therapeutics, Inc. (VKTX) the Healthcare Stocks Stock Everyone's About to Talk About?
September 26, 2026  |  kalkinemedia.comK
Bronze bull and bear statues face off in an urban financial district at sunset.
MarketBeat Week in Review – 09/21 - 09/25 (VKTX)
...
September 26, 2026  |  marketbeat.comhttps://www.marketbeat.com/articles/marketbeat-week-in-review-09-21-09-25/
Viking Therapeutics, Inc. $VKTX Shares Newly Acquired by Bank of America Corp DE
September 26, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-viking-therapeutics-inc-vktx-shares-newly-acquired-by-bank-of-america-corp-de-2026-09-26/
Viking Therapeutics (NASDAQ:VKTX) Stock Bumped Up to "Sell" by Wall Street Zen
September 26, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31051374

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Micron, Coherent and Tower Semiconductor: 3 Stocks Built on AI's Bottlenecks
NVIDIA Just Named AI's Next Bottleneck—And These 3 Stocks Sit Right In It
By Bridget Bennett | September 20, 2026
Data center hallway with rows of server racks and cables, plus a monitoring room with computer screens in the background.
AI Token Costs Are Changing the Hardware vs. Software Debate
By Jeffrey Neal Johnson | September 6, 2026
A Tesla concept vehicle with illuminated front light bar drives on a road against a city skyline at dusk.
Tesla’s Robotaxi Launch Wasn’t the Moment Investors Expected
By Sam Quirke | September 8, 2026
Stacks of coins rising on a desk beside a computer with an upward stock chart, with a blurred city skyline behind.
3 Dividend Kings to Buy While They’re Still Beaten Down
By Thomas Hughes | September 14, 2026
Viking Therapeutics logo displayed among laboratory glassware, a vial, and a syringe in a lab setting.
Viking's Obesity Edge May Be Staying Power, Not Weight Loss
By Chris Markoch | September 23, 2026
Celcuity stock logo

Celcuity NASDAQ:CELC

$78.61 -0.91 (-1.14%)
As of 09:40 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Celcuity Inc., a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, advanced or metastatic breast cancer, and metastatic castration resistant prostate cancer. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. The company was founded in 2011 and is headquartered in Minneapolis, Minnesota.

Cullinan Therapeutics stock logo

Cullinan Therapeutics NASDAQ:CGEM

$15.06 -0.29 (-1.86%)
As of 09:39 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Cullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. In addition, the company's development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib. Cullinan Therapeutics, Inc. was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Telix Pharmaceuticals stock logo

Telix Pharmaceuticals NASDAQ:TLX

$10.88 -0.09 (-0.84%)
As of 09:40 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals. The Product Development segment develops radiopharmaceutical products for commercialization. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TLX250, TLX591, and TLX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia.

Viking Therapeutics stock logo

Viking Therapeutics NASDAQ:VKTX

$32.30 -0.30 (-0.93%)
As of 09:40 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas